<DOC>
	<DOC>NCT01859728</DOC>
	<brief_summary>To evaluate safety and efficacy of the combination cisplatin plus irinotecan in the treatment of biliary tract cancer.</brief_summary>
	<brief_title>GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer</brief_title>
	<detailed_description />
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Antiemetics</mesh_term>
	<criteria>biopsyproven gallbladder or biliary tract cancer; Recurrent, metastatic or unresectable disease; Chemona√Øve. Not candidates to curativeintent treatment, such as surgery or radiationtherapy; Measurable disease according to RECIST 1.1; ECOG 02; Adequate hematologic and biochemistry tests; Creatinine clearance &gt;= 60ml/min. Known hypersensibility or previous therapy with cisplatin, gemcitabine or irinotecan; Chronic immunosuppressive therapy; Known CNS metastasis; Previous diagnosis of other cancer; Chronic or acute active infection, except asymptomatic HIV infection; Active bleeding; Any severe medical condition; Pregnant or lactating women, or with childbearing potential;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>biliary cancer</keyword>
	<keyword>irinotecan</keyword>
	<keyword>cisplatin</keyword>
	<keyword>gemcitabine</keyword>
</DOC>